Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc
(CSE:
CMND
)
N/A
UNCHANGED
Last Price
Updated: 3:54 PM EDT, Mar 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Clearmind Medicine Inc
< Previous
1
2
3
4
Next >
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
May 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
May 07, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Applies to Cease Being a Reporting Issuer in Canada
April 30, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
April 17, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
April 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine CEO Issues Letter to Shareholders
April 09, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
March 27, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
March 19, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
March 13, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
March 13, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
February 27, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
February 27, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
February 23, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
February 05, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
February 01, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY0) Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement
January 17, 2024
Via
Investor Brand Network
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
January 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
January 11, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Completed Type A Meeting with the FDA
January 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
January 04, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
January 04, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
December 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
December 05, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
December 01, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
November 28, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
November 27, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces 1-for-30 Reverse Share Split
November 21, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance
November 17, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.